In this issue:
Prediction of bone marrow fibrosis from complete blood count in MPNs
Myelofibrosis risk stratification is enhanced with an HSPC-derived gene expression signature
Dual-epitope targeting of mutant CALR ± ruxolitinib promising for MPNs
Ropeg may be a novel efficacious therapeutic for early myelofibrosis
SENTRY: Encouraging efficacy of selinexor + ruxolitinib for JAK inhibitor–naïve myelofibrosis
AI algorithm accurately differentiates pre-fibrotic myelofibrosis from ET
JUMP analysis finds benefit to ruxolitinib regardless of baseline or new-onset anaemia
Please login below to download this issue (PDF)